Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Buchler

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 11, 2012
Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER studyY Lebranchu, R Snanoudj, O Toupance, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 9, 2009
Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept studyY Lebranchu, A Thierry, O Toupance, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 19, 2016
Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 GenotypeN Pallet, I Etienne, M Buchler, et al.
Clinical Pharmacology and Therapeutics|April 16, 2010
Optimization of initial tacrolimus dose using pharmacogenetic testingE Thervet, M A Loriot, S Barbier, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 16, 2015
Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrationsN Pallet, A-S Jannot, M El Bahri, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 7, 2016
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic ScreeningC Damon, M Luck, L Toullec, et al.
Transplantation Proceedings|March 15, 2000
Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study GroupY Lebranchu, P Aubert, F Bayle, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 1, 2011
Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter studyT Kofman, P Grimbert, F Canouï-Poitrine, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 11, 2012
Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER studyY Lebranchu, R Snanoudj, O Toupance, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 9, 2009
Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept studyY Lebranchu, A Thierry, O Toupance, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 19, 2016
Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 GenotypeN Pallet, I Etienne, M Buchler, et al.
Clinical Pharmacology and Therapeutics|April 16, 2010
Optimization of initial tacrolimus dose using pharmacogenetic testingE Thervet, M A Loriot, S Barbier, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 16, 2015
Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrationsN Pallet, A-S Jannot, M El Bahri, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 7, 2016
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic ScreeningC Damon, M Luck, L Toullec, et al.
Transplantation Proceedings|March 15, 2000
Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study GroupY Lebranchu, P Aubert, F Bayle, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 1, 2011
Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter studyT Kofman, P Grimbert, F Canouï-Poitrine, et al.
Pageof 5